GLP-1 Agonists Market worth $170.75 billion in 2033
The report "GLP-1 Agonists Market by Product (Ozempic, Wegovy, Mounjaro), Molecule (semaglutide, tirzepatide), Type (Patented, Biosimilars), Format (Single dose, Multi-dose, Tablets), ROA (SC, Oral), Indication (Diabetes, Obesity) - Global Forecast to 2033 ", is expected to reach USD 170.75 billion in 2033 from USD 64.42 billion in 2025 at a CAGR of 13.0% during the forecast period. Some factors contributing to the growth of the global GLP-1 agonists market include growing demand for the GLP-1 agonist drug class, owing to the growing prevalence of diabetes and obesity. However, patent expiry and generics development, along with affordability issues, especially in developing countries, are some of the factors expected to restrain market growth.
Browse 400 market data Tables and 45 Figures spread through 300 Pages and in-depth TOC on "GLP-1 Agonists Market by Product (Ozempic, Wegovy, Mounjaro), Molecule (semaglutide, tirzepatide), Type (Patented, Biosimilars), Format (Single dose, Multi-dose, Tablets), ROA (SC, Oral), Indication (Diabetes, Obesity) - Global Forecast to 2033 "
View detailed Table of Content here - https://www.marketsandmarkets.com/Market-Reports/glp-1-analogues-market-218746186.html
By indication, diabetes accounted for the largest market share in the GLP-1 agonists market in 2024.
Based on indication, the GLP-1 Agonists market is segmented into diabetes, obesity and other indications. In 2024, the diabetes segment dominated the market. GLP-1 agonists are becoming a key drug class in diabetes care because of their proven benefits in glycemic control, weight reduction, and cardiovascular risk mitigation. Strong clinical adoption, broad regulatory approvals, and substantial patient populations maintain diabetes as the dominant indication within the GLP-1 market.
By route of administration, the subcutaneous segment accounted for the largest market share in the GLP-1 agonists market in 2024.
Based on route of administration, the GLP-1 Agonists market is segmented into subcutaneous and oral routes. In 2024, the subcutaneous segment dominated the market. The large share of this market can be attributed to its established effectiveness and patient acceptance for GLP-1 agonists, enabling efficient and controlled drug delivery with sustained release. This administration route allows ease of use with self-injection devices that improve adherence and convenience.
The Asia Pacific region is expected to register the highest CAGR during the forecast period.
Based on the region, the GLP-1 agonists market is segmented into six regions: North America, Europe, the Asia Pacific, Latin America, the Middle East, and Africa. The Asia Pacific region is expected to register the highest growth rate during the forecast period, due to the high prevalence of obesity and diabetes, coupled with the rapid adoption of innovative metabolic therapies. Strong healthcare reimbursement frameworks, robust clinical infrastructure, and early regulatory approvals accelerate product uptake. Additionally, significant investments in manufacturing expansions and extensive marketing efforts by leading pharmaceutical companies fuel market momentum in this region.
The market for GLP-1 agonists is highly consolidated, with key players strategizing to capture the market. Prominent players in the GLP-1 agonists market are Novo Nordisk (Denmark), Eli Lilly (US), and Sanofi (France), among other players.
About MarketsandMarkets™
MarketsandMarkets™ has been recognized as one of America's Best Management Consulting Firms by Forbes, as per their recent report.
MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe.
Today, 80% of Fortune 2000 companies rely on MarketsandMarkets, and 90 of the top 100 companies in each sector trust us to accelerate their revenue growth. With a global clientele of over 13,000 organizations, we help businesses thrive in a disruptive ecosystem.
The B2B economy is witnessing the emergence of $25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.
Built on the 'GIVE Growth' principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our Market Intelligence Cloud, KnowledgeStore™, which integrates research and provides ecosystem-wide visibility into revenue shifts.
To find out more, visit www.MarketsandMarkets™.com or follow us on Twitter , LinkedIn and Facebook .
Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA: +1-888-600-6441
Email: sales@marketsandmarkets.com
Visit Our Website: https://www.marketsandmarkets.com/
- Triangulate with your Own Data
- Get Data as per your Format and Definition
- Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
- Any level of Personalization
- What are the Known and Unknown Adjacencies Impacting the GLP-1 Agonists Market
- What will your New Revenue Sources be?
- Who will be your Top Customer; what will make them switch?
- Defend your Market Share or Win Competitors
- Get a Scorecard for Target Partners
